Opko has acquired Pharmacos Exakta, including a manufacturing facility owned by an affiliate, for cash and shares of Opko Common Stock.
Phillip Frost, chairman and CEO of Opko, said: “We believe this acquisition will provide Opko with an excellent platform to expand manufacturing and distribution capabilities for a wide range of products while, at the same time, maintaining our original interest in ophthalmology.
“It also furthers our strategy of expanding commercial activities while we continue to develop our important diagnostic and therapeutic products, as well as our flu vaccine.”